101.50MMarket Cap-771P/E (TTM)
0.860High0.800Low1.02MVolume0.820Open0.826Pre Close847.71KTurnover0.90%Turnover RatioLossP/E (Static)125.31MShares1.95052wk High-0.64P/B92.23MFloat Cap0.61752wk Low--Dividend TTM113.87MShs Float49.005Historical High--Div YieldTTM7.29%Amplitude0.617Historical Low0.832Avg Price1Lot Size
Karyopharm Therapeutics Stock Forum
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics (Nasdaq: KPTI)announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.
Phase 1 trial data showed pr...
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 Sentry Trial in Myelofibrosis
No comment yet